Summary
Five patients out of 71 with rheumatoid arthritis (RA), who received D-penicillamine, developed myasthenia gravis (MG) within a two-year period. They all responded promptly to discontinuation of the drug and pyridostigmine administration. None of the patients had anti-Ro(SSA) antibodies or features of Sjögren's syndrome, whereas three of the five had the HLA-DR1 phenotype. The relatively high frequency of MG observed in our population, along with its unpredictability and potentially serious sequelae, necessitates its inclusion in the list of side effects of D-penicillamine routinely discussed with the patient, prior to initiation of the treatment. Full alertness of both the patient and the physician to even minor initial myasthenic symptoms, that dictate immediate discontinuation of the drug, is of obvious importance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bucknall, C. Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis. Proc R Soc Med 1977, 70 (suppl 3), 114–117.
Albers, J.W., Hodach, R.J., Kimmel, D.W., Treacey, W.L. Penicillamine associated myasthenia gravis. Neurology 1980, 30, 1246–1250.
Torres, C.F., Griggs, R.C., Baum, J., Penn, A.S. Penicillamine induced myasthenia gravis in progressive systemic sclerosis. Arthritis Rheum 1980, 23, 505–508.
Bever, C.T., Chang, H.W., Penn, A.S., Jaffe, I.A., Bock, E. Penicillamine induced myasthenia gravis. Effects of penicillamine on acetylcholine receptor. Neurology 1982, 32, 1077–1082.
Garlepp, M.J., Dawkins, R.L., Christiansen, F.T. HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. Br Med J 1983, 286, 338–340.
Delamere, J.P., Jobson, S., Mackintosh, L.P., Wells, L., Walton, K.W. Penicillamine induced myasthenia in rheumatoid arthritis: its clinical and genetic features. Ann Rheum Dis 1983, 42, 500–504.
Benvenista, M., Crouzet, J., Hombert, J.C., Lessana, M., Camus, J.P., Hewitt, J. Pemphigus induits par la D-penicillamine dans la polyarthrite rheumatoide. Nouv Presse Med 1975, 4, 3125–3128.
Chalmers, A., Thompson, D., Stein, H.E., Reid, G., Patterson, A.C. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med 1982, 97, 659–663.
Morgan, G.J., McGuire, J.L., Ochoa, J. Penicillamine induced myositis in rheumatoid arthritis. Muscle Nerve 1981, 4, 137–140.
Stenlieb, I., Bennet, B., Scheinberg, I.H. D-penicillamine induced Goodpasture's syndrome in Wilson's disease. Ann Intern Med 1975, 82, 673–676.
Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., Medsger, T.A., Mitchell, T.M., Neustadt, D.H., Pinals, R.S., Schaller, J.G., Sharp, J.T., Wilder, R.L., Hunder, G.G. The American Rheumatism Association criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31, 315–324.
Andonopoulos, A.P., Galanopoulou, V., Drosos, A.A., Moutsopoulos, H.M. Rheumatoid arthritis in Greece. Manifestations in different age groups. Rheumatol Int 1987, 7, 101–105.
Newson-Davis, J., Pinching, A., Vincent, A.J., Wilson, S.G. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 1978, 28, 266–272.
Andonopoulos, A.P., Papasteriades, C.A., Drosos, A.A., Dimou, G.S., Moutsopoulos, H.M. HLA antigens in Greek patients with systemic lupus erythematosus. Clin Exp Rheumatol 1990, 8, 1–4.
Desmedt, J.E. Presynaptic mechanisms in myasthenia. Ann NY Acad Sci 1966, 135, 209–246.
Desmedt, J.E., Borenstein, S. The testing of neuromuscular transmission. Handbook Clin Neurol 1970, 7, 104–115.
Svejgaard, A., Jersild, D., Nielsen, L.S., Bodmer, W.F. HLA antigens and disease; statistical and genetic considerations. Tissue Antigens 1974, 4, 95–105.
Virella, G., Lopez-Virella, M. Effect of therapeutically useful thiols on immunoglobulins. Clin Exp Immunol 1970, 7, 85–108.
Ruiz-Torres, A. Zur pharmakokinetik und zum stottmechsel von D- und L-Penicillamin. Arzneim Forsch 1974, 24, 914–917.
Skopouli, F.N., Andonopoulos, A.P., Moutsopoulos, H.M. Clinical implications of the presence of anti-Ro(SSA) antibodies in patients with rheumatoid arthritis. J Autoimmunity 1988, 3, 381–388.
Panayi, G.S., Wooley, P., Batchelor, J.R. Genetic basis of RA HLA antigen, disease manifestations and toxic reactions to drugs. Br Med J 1978, 11, 1326–1328.
Wooley, P.H., Griffin, J., Panayi, G.S., Batchelor, J.R., Welsh, K.I., Gibson, T.J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980, 303, 300–302.
Smolen, J.S., Klippel, J.H., Penner, E., Reichlin, M., Steinberg, A.D., Chused, T.M., Scherac, O., Graninger, W., Hartter, E., Zielinski, C.C., Wolf, A., Davey, R.J., Mann, D.L., Mayr, W.R. HLA-DR antigens in systemic lupus erythematosus:association with specificity of autoantibody responses to nuclear antigens. Ann Rheum Dis 1987, 46, 457–462.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Andonopoulos, A.P., Terzis, E., Tsibri, E. et al. D-penicillamine induced myasthenia gravis in rheumatoid arthritis: An unpredictable common occurrence?. Clin Rheumatol 13, 586–588 (1994). https://doi.org/10.1007/BF02242998
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02242998